Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034176 · ClinicalTrials.gov registry record · Phase 4
BK Treatment Study
A Phase 4 study of BK Viremia, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 8
- Study locations
NCT01034176 is a Phase 4 study of BK Viremia that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 43 participants. The trial reports 8 study locations across 4 states.
The verdict
NCT01034176, a Phase 4 study of BK Viremia, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 8
- Study locations
Study Summary
Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or eliminating BK virus in the blood.
Conditions Studied
Interventions
- DRUG placebo
- DRUG levofloxacin
Study Locations (8)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Lahey Clinic Medical Center - Burlington
- UMASS Memorial Medical Center - Worcester
New York
- Montefiore Medical Center - The Bronx
Vermont
- Fletcher Allen Health Care/University of Vermont - Burlington
Wisconsin
- University of Wisconsin Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01034176
The ClinicalTrials.gov registry entry for NCT01034176 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with BK Viremia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01034176 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, Vermont.
Frequently Asked Questions
What is clinical trial NCT01034176 about?
NCT01034176 is a clinical study titled "BK Treatment Study". Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or eliminating BK virus in the blood.
What is the current status of trial NCT01034176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2009-02. Estimated completion is 2012-10.
What conditions does trial NCT01034176 study?
This clinical trial studies the following conditions: BK Viremia.
What interventions are being tested in trial NCT01034176?
The interventions under investigation include: placebo (DRUG), levofloxacin (DRUG).
Who is sponsoring clinical trial NCT01034176?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01034176 being conducted?
This trial has 8 study locations across Massachusetts, New York, Vermont, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.